Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News ADA 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

L.A. McKeown

June 28, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Amylin Analogue Boosts Weight Loss When Added to GLP-1

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Top General Cardiology and Prevention News of 2024

August 2024 Dispatch for the CV Team

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content